Industry Overview

US CDMO market was valued at $92.5 billion in 2025 and is projected to reach $171.3 billion by 2035, growing at a CAGR of 6.4% during the forecast period (2026–2035). The US healthcare CDMO market is expanding steadily as pharmaceutical and biotechnology companies increasingly outsource both development and manufacturing to specialized service providers. Growth is driven by the rising demand for biologics, advanced therapies, and complex dosage forms requiring sophisticated production capabilities. Strong investment in research and development, coupled with a robust regulatory framework, supports efficient scale-up and commercialization. Key players are enhancing manufacturing infrastructure, adopting advanced technologies, and expanding capacity to meet evolving client needs. Strategic collaborations and long-term contracts with pharmaceutical innovators further strengthen market dynamics. Collectively, these factors are sustaining the upward trajectory of the US CDMO market through the forecast period.

Market Dynamics

Rise of Advanced Therapy Manufacturing

In the US, CDMOs are increasingly focused on biologics, cell and gene therapies, and complex injectable formulations. Growth is fueled by expanding clinical pipelines and rising approvals for advanced treatments. Leading service providers are investing in specialized facilities, high-containment systems, and single-use technologies. The adoption of continuous manufacturing and automation is improving production efficiency and scalability. These developments position US CDMOs as key partners for innovative therapy commercialization.

Integration of End-to-End Development and Manufacturing

Pharmaceutical and biotech companies are increasingly partnering with CDMOs that offer comprehensive services, from early-stage development to commercial manufacturing. This integrated approach reduces technical risk, accelerates time-to-market, and ensures supply continuity. Major CDMOs are expanding analytical, regulatory, and commercial-scale capabilities to support clients’ full lifecycle needs. Long-term contracts and strategic alliances are becoming more common. This trend strengthens client relationships and supports sustained market growth.

Market Segmentation

• Based on the services, the market is segmented into contract development and contract manufacturing.

Contract Manufacturing Segment to Lead the Market with the Largest Share

Contract manufacturing is the leading sub-segment in the US CDMO market, driven by strong demand for large-scale production of small molecules, biologics, and complex drug formulations. Pharmaceutical and biotechnology companies increasingly outsource manufacturing to optimize costs, manage capacity constraints, and ensure compliance with stringent regulatory standards. Leading CDMOs offer advanced facilities, high-containment systems, and expertise in sterile injectables and high-potency APIs. Recent trends include the adoption of continuous manufacturing, single-use technologies, and facility expansions to support global supply chains. Strategic partnerships with pharmaceutical innovators further strengthen market position. This sub-segment dominates due to its critical role in enabling scalable and reliable production.

Contract Development: A Key Segment in Market Growth

Contract development services are expanding steadily as companies seek external expertise for early and mid-stage drug development. Growth is fueled by demand for formulation design, process optimization, analytical testing, and regulatory support. CDMOs with integrated development capabilities are increasingly preferred, particularly for biologics, complex molecules, and high-value therapies. Recent trends highlight the use of digital modeling, quality-by-design approaches, and scalable process development. Contract development reduces technical risk before commercialization and supports accelerated product launches. This sub-segment continues to gain strategic importance in the US CDMO market.

Market Players Outlook

The major companies operating in the US CDMO market include Thermo Fisher Scientific Inc., Lonza Group AG, WuXi AppTec Co., Ltd., WuXi Biologics Co., Ltd., and Eurofins Scientific SE, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In October 2025, Intricon and Minnetronix Medical, two prominent contract development and manufacturing organizations (CDMOs) serving the medical technology industry, combined to form Forj Medical. Forj Medical offers end-to-end capabilities from concept through commercial scale in system design, microelectronics, precision molding, and advanced manufacturing. The company’s fully integrated CDMO service offering supports medical device OEMs in developing and scaling complex technologies with speed and precision.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the US CDMO market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.